Broad access and affordability solutions help you get your patients started on IZERVAY

We know access matters

This is why IZERVAY My Way was built by retina for retina to help streamline access, affordability, and reimbursement support that you can count on

91% of patients

covered by any Medicare plan can start IZERVAY as their first branded GA treatment5*

*Coverage for IZERVAY may be subject to prior authorization requirements. Percentage listed herein includes Medicare Part B and Medicare Advantage covered lives where IZERVAY is covered (unrestricted) or covered subject to prior authorization, without a step edit in place. Based on Managed Markets Insight & Technology data, June 2025.

Enroll your patients today

Logo of IZERVAY My Way

IZERVAY My Way can help with benefits investigations (BI) and the patient enrollment process

Enrollment portal icon

Enroll on the IZERVAY My Way portal

Enroll patients online, upload documents, and check patient enrollment all in one place

Visit the portal
Enrollment form icon

Download the IZERVAY My Way enrollment form and submit it via email or fax

Email:
Support@IZERVAYMyWay.com
Fax:
1-833-C5MYWAY (1-833-256-9929)

Download Enrollment Form

See IZERVAY My Way offerings

IZERVAY My Way offers flexible options and dedicated experts for:

Getting started icon

Getting Started

  • Portal enrollment
  • Benefits investigation
Icon of a key

Access

  • Prior authorization (PA) information and assistance
  • PA appeals and denials information and assistance
  • Benefits reverification
Icon of a dollar sign

Affordability

  • IZERVAY Commercial Copay Program
  • Patient Assistance Program§
Reimbursement icon

Reimbursement

  • Billing and coding||
  • Claims appeals information and assistance

Affordability

IZERVAY My Way offers potential affordability options for your patients across insurance types

Commercial

IZERVAY Commercial Copay Program

  • Eligible commercial patients may pay as little as $0 copay for IZERVAY, subject to an assistance limit of up to $20,000 per calendar year
  • Eligible patients may pay as little as $0 copay for IZERVAY administrations, subject to an assistance limit of up to $1,500 per calendar year
  • Click here to view full IZERVAY Commercial Copay Program Terms and Conditions

Underinsured/uninsured

Patient Assistance Program

  • Eligible underinsured/uninsured patients may be able to receive IZERVAY at no cost§
  • Patients must meet program eligibility requirements, including financial criteria
  • Click here to view full Astellas Patient Assistance Program Terms and Conditions

The healthcare provider remains responsible for populating all clinical content.

Eligibility criteria and terms and conditions apply. Patients are not eligible for the program if they are self-paying or if the patient is enrolled in a state or federal healthcare program. There is a maximum benefit limit of $20,000 for product cost share per calendar year and $1,500 for the administration cost share reimbursement to the patient. If the patient’s total out-of-pocket bill exceeds the cap established by Astellas, the patient will be responsible for the additional balance. Patients residing in Massachusetts and patients receiving IZERVAY treatment in Massachusetts may be eligible for copay assistance for the cost of IZERVAY only, and are not eligible for copay assistance for the administration of IZERVAY. Offer is not health insurance and is void where prohibited by law. Astellas reserves the right to revoke, rescind, or amend this offer without notice for any reason. For full terms and conditions, visit IZERVAYecp.com/PatientSupport.

§Eligibility criteria and terms and conditions apply. For full terms and conditions, visit IZERVAYecp.com/PatientSupport.

||The responsibility to determine coverage, reimbursement, and appropriate coding for a patient remains at all times with the provider. Information provided by IZERVAY My Way should in no way be considered a guarantee of coverage or reimbursement for any product or service.

Learn how to get started with support from a dedicated IZERVAY My WAY Access Coordinator

Visit IZERVAY My Way

Find a practice

Next page

IMPORTANT SAFETY INFORMATION AND INDICATION

CONTRAINDICATIONS

IZERVAY® is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.

WARNINGS AND PRECAUTIONS

Endophthalmitis and Retinal Detachments

  • Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

Neovascular AMD

  • In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.

Increase in Intraocular Pressure

  • Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.

INDICATION

IZERVAY (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Please see full Prescribing Information for more information.

To request medical information, please call 1-800-727-7003 or send an email to medinfo.americas@astellas.com. To report an adverse event or product complaint, please call 1-800-727-7003 or send an email to safety-us@astellas.com.

IMPORTANT SAFETY INFORMATION AND INDICATION

CONTRAINDICATIONS

IZERVAY® is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.

WARNINGS AND PRECAUTIONS

Endophthalmitis and Retinal Detachments

  • Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

Neovascular AMD

  • In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.

Increase in Intraocular Pressure

  • Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.

INDICATION

IZERVAY (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Please see full Prescribing Information for more information.

To request medical information, please call 1-800-727-7003 or send an email to medinfo.americas@astellas.com. To report an adverse event or product complaint, please call 1-800-727-7003 or send an email to safety-us@astellas.com.